Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4166 On Other Exchanges
4166 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

orient pharma co ltd (4166) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORIENT PHARMA CO LTD (4166)

Related News

No related news articles were found.

orient pharma co ltd (4166) Related Businessweek News

No Related Businessweek News Found

orient pharma co ltd (4166) Details

Orient PHARMA Co., Ltd. engages in the research and development, manufacture, and sale of drugs in Taiwan and internationally. Its product portfolio includes GlucoMet, a tablet for type II diabetes; Sonimax, a capsule for insomnia; Mycros, a capsule for hypertension; Immufine, a capsule for rejection in organ transplantation; Kytron, an injection for nausea and vomiting associated with cancer chemotherapy or radiotherapy; and Lafuzo, a tablet for benigh prostatic hyperplasia. The company is also developing oral syrup product, which is in Phase II clinical trials for treating sialorrhoea; capsule product for tuberculosis that is in Phase I clinical trials; and capsule product, which is in Phase III clinical trials for attention deficit hyperactivity disorders. In addition, it offers product registration or other services; and clinical research services. Orient PHARMA Co., Ltd. offers its products through sales representatives. The company was founded in 2008 and is based in Taipei, Taiwan. Orient PHARMA Co., Ltd. is a subsidiary of Orient EuroPharma Co., Ltd.

Founded in 2008

orient pharma co ltd (4166) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

orient pharma co ltd (4166) Key Developments

Orient Pharma Co., Ltd., Annual General Meeting, Jun 17, 2015

Orient Pharma Co., Ltd., Annual General Meeting, Jun 17, 2015.

Orient Pharma Co., Ltd., Annual General Meeting, Jun 12, 2014

Orient Pharma Co., Ltd., Annual General Meeting, Jun 12, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4166:TT 27.68 TWD +0.05

4166 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4166.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4166 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.9x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ORIENT PHARMA CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at